|[January 02, 2013]
Fluidigm Completes C1™ Single-Cell Auto Prep System Early Access Program
SOUTH SAN FRANCISCO, Calif. --(Business Wire)--
Fluidigm Corporation (NASDAQ:FLDM) announced that its C1™
Single-Cell Auto Prep system Early Access Program (EAP) has concluded.
The EAP originally targeted 25 customers that would gain early access to
the new platform, protocols and consumables. The program attracted
significant interest, filling up weeks before its expected end-of-2012
deadline. To accommodate interested customers, the company allowed
oversubscription of the program.
"We have been excited and humbled by the enthusiastic reception the C1
system has received. Our customers have demonstrated a high level of
interest in the C1 Early Access Program and the number of
them that have signed up to participate is clearly a record for
Fluidigm," said Gajus Worthington, Fluidigm President and Chief
Executive Officer. "The C1 system is the most powerful device
for single-cell genomics available today because it enables a wide range
of genomic applications for our customers to discover and validate novel
transcripts in heterogeneous cell populations. We are just at the
beginning stages of an important market that will fuel genomic discovery
over the next decade."
The C1 Single-Cell Auto Prep System enables researchers to
study cell differentiation, measure individual cell responses to
specific stimuli, verify critical disease biomarkers, validate RNAi
knockdown, and conduct candidate drug screens. "We are thrilled to be
working with an elite set of customers in our Early Access Program. They
represent a global group of scientists from the world's leading genomics
research institutions. They have a genuine enthusiasm about the prospect
of applying C1 system capabilities to their research and many
have begun experimental design and initial work on the systems. We
believe they will generate some breakthrough biological discoveries,"
"As one of the first academic users of the Fluidigm C1
Single Cell Auto Prep system, my research team at UC San Diego will
benefit by the development of this advanced, single-cell technology. The
system will support our commitment to engaging our expertise in RNA and
genome-wide computational methods to deciphering heterogeneity in RNA
processing in single cells, especially in the developing nervous system
and in neurodegenerative diseases," noted Gene Yeo, PhD, MBA, Assistant
Professor, Department of Cellular and Molecular Medicine, UC San Diego.
"Single-cell analyses are critical for our cellular reprogramming
research because each cell undergoes a fate change in a unique way.
Averaging the changes over many cells masks important reprogramming
events in individual cells that dramatically alter their fate," said
Deepak Srivastava, Director of Cardiovascular and Stem Cell Research,
Gladstone Institutes. "We are thrilled to be part of the Fluidigm C1
Single-Cell Auto Prep System's Early Access Program and look forward to
using this exciting new technology to accelerate our single-cell
"We are delighted to be one of thefirst users of the Fluidigm C1
system. One of our first projects will involve the analysis of neurons
directly converted from skin fibroblasts. The C1 system will
allow us to look at markers specific for subtypes of neurons at a
single-cell resolution while assessing the conversion rate collectively
in the population of converted neurons," said Seth Crosby, Director,
Partnerships and Alliances at Washington University School of Medicine.
"The Fluidigm C1 Single-Cell Auto Prep System will be
available in our facility on a fee-for-service basis for both WashU and
non-WashU researchers," Crosby added.
"The C1 system allows us to capture up to 96 individual cells
at one time and prepare them for further analysis," says Vivian Gersuk,
PhD, manager of the Genomics Core Laboratory of the Benaroya Research
Institute. "We can study hundreds to thousands of genes in each of these
cells, allowing us to produce huge amounts of data in a matter of hours."
The C1 Single-Cell Auto Prep System is the first commercially
available platform for automated isolation and preparation of individual
cells for genomic analysis. The C1 system, based on
Fluidigm's innovative microfluidic technology, enables a researcher to
isolate, process and summarize the unique gene expression profiles of
individual cells rapidly and reliably. For the first time, a researcher
can easily isolate single cells, extract RNA, then reverse transcribe
and amplify mRNA transcripts to ultimately detect and analyze cell
activity - dramatically reducing the variability and technical errors
caused by multi-platform workflows that have been previously used. By
delivering an integrated workflow, Fluidigm is enabling researchers to
implement targeted gene expression, miRNA analysis and whole
transcriptome analysis in a more efficient and cost-effective manner.
Fluidigm's Early Access Program for the C1 system provided a
select group of customers with the preferred access of instruments
equipped with a package of startup consumables (integrated fluidic
circuits (IFCs) and reagents), and provides first access to new
application protocols or analysis tools. The EAP participants actively
contribute information about their experiences with the C1
system to Fluidigm to accelerate the development of new platform
capabilities. The C1 system is specifically designed to work
seamlessly with the Fluidigm BioMark™ HD System to enhance the workflow
and reliability of data for scientists studying single-cell genomics.
The C1 Single-Cell Auto Prep System consists of:
C1 Single-Cell Auto Prep instrument that provides
breakthrough bench-top automation of isolation, lysis and
amplification performed on single cells.
C1 Single-Cell Auto Prep Array IFCs that facilitate capture
and highly paralleled preparation of up to 96 individual cells.
C1 Single-Cell Auto Prep Reagent Kit, a pre-formulated
"ready to use" reagent kit that supports cell suspension, lysis and
For more information about the C1 Single Cell Auto Prep
system, please visit www.fluidigm.com/c1system.
Use of Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements relating to Fluidigm's new C1 system,
Fluidigm's expectations with respect to the development of a market for
single cell genomic analysis and discovery, Fluidigm's plans,
objectives, expectations and strategies relating to the C1
system, and potential developments in the markets that the C1
system is anticipated to target. Forward-looking statements are subject
to numerous risks and uncertainties that could cause actual results to
differ materially from currently anticipated results, including
challenges inherent in developing, manufacturing, and launching new
products and risks relating to research and development activities and
the growth of new and developing markets. Information on these and
additional risks affecting Fluidigm's business and operating results are
contained in its filings with the Securities and Exchange Commission,
including its most recently filed Quarterly Report on Form 10-Q for the
quarter ended September 30, 2012. These forward-looking statements speak
only as of the date hereof and Fluidigm disclaims any obligation to
update these statements.
Fluidigm (NASDAQ:FLDM) develops, manufactures and markets microfluidic
systems for growth markets in the life science and agricultural
biotechnology, or Ag-Bio, industries. Fluidigm's proprietary
microfluidic systems consist of instruments and consumables, including
integrated fluidic circuits (IFCs), assays and other reagents. These
systems are designed to significantly simplify experimental workflow,
increase throughput and reduce costs, while providing the excellent data
quality demanded by customers. Fluidigm actively markets four
microfluidic systems, including thirteen different IFCs, to leading
academic institutions, diagnostic laboratories, and pharmaceutical,
biotechnology and Ag-Bio companies. Fluidigm products are marketed for
research purposes only (not for diagnostic use).
For more information, please visit www.fluidigm.com.
Fluidigm, the Fluidigm logo, C1 and BioMark, are trademarks
or registered trademarks of Fluidigm Corporation. All other trademarks
are the property of their respective owners.
[ Back To TMCnet.com's Homepage ]